Beneficial effects of Lactobacillus plantarum on glycemia and homocysteine levels in postmenopausal women with metabolic syndrome

Barreto, Fabíola Málaga; Simão, Andréa Name Colado; Morimoto, Helena Kaminami; Lozovoy, Marcell Alysson Batisti; Dichi, Isaías; Miglioranza, Lucia Helena da Silva

doi:10.1016/j.nut.2013.12.004

Cited by 111 publications

(77 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other studies [106][107][108][109][110][111][112][113][114][115][116][117][118] have demonstrated the beneficial effects exerted by probiotics containing Lactobacillus strains on animals and human subjects, showed in Table 2 and Table 3, respectively.…”

Section: Probioticsmentioning

confidence: 96%

Gut microbiota and metabolic syndrome

Festi¹,

Schiumerini²,

Eusebi³

et al. 2014

WJG

424

289

View full text Add to dashboard Cite

Gut microbiota exerts a significant role in the pathogenesis of the metabolic syndrome, as confirmed by studies conducted both on humans and animal models. Gut microbial composition and functions are strongly influenced by diet. This complex intestinal "superorganism" seems to affect host metabolic balance modulating energy absorption, gut motility, appetite, glucose and lipid metabolism, as well as hepatic fatty storage. An impairment of the fine balance between gut microbes and host's immune system could culminate in the intestinal translocation of bacterial fragments and the development of "metabolic endotoxemia", leading to systemic inflammation and insulin resistance. Diet induced weight-loss and bariatric surgery promote significant changes of gut microbial composition, that seem to affect the success, or the inefficacy, of treatment strategies. Manipulation of gut microbiota through the administration of prebiotics or probiotics could reduce intestinal low grade inflammation and improve gut barrier integrity, thus, ameliorating metabolic balance and promoting weight loss. However, further evidence is needed to better understand their clinical impact and therapeutic use.

show abstract

Section: Probioticsmentioning

confidence: 96%

Gut microbiota and metabolic syndrome

Festi¹,

Schiumerini²,

Eusebi³

et al. 2014

WJG

424

289

View full text Add to dashboard Cite

show abstract

“…Several clinical trials have shown the effect of probiotics on the reduction of glucose, insulin, HbA 1c and other glycemic factors for type 2 diabetes mellitus (T2DM) [10][11][12][13][14][15][16][17][18][19] and other diabetes or metabolic syndrome (defined as MS) [9,[20][21][22][23][24][25][26]. However, their dosages, bacterial strains and time of therapy were short of homogeneity.…”

Section: Introductionmentioning

confidence: 99%

Multiple effects of probiotics on different types of diabetes: a systematic review and meta-analysis of randomized, placebo-controlled trials

Wang

Juan

et al. 2017

Journal of Pediatric Endocrinology and Metabolism

View full text Add to dashboard Cite

Background: A systematic review and meta-analysis was designed to evaluate the effect of probiotics on diabetes and its associated risk factors. Methods: We systematically searched the Cochrane Library, PubMed, EMBASE and Web of Science to June 2016. We also hand-searched the citation lists of included studies and previously identified systematic reviews to identify further relevant trials. Our primary outcome variables included glucose, glycated hemoglobin (HbA 1c ) and insulin. The pooled standardized mean difference was used to compare the effect between the probiotics and controlled groups, and the pooled standardized mean difference effect size with a 95% confidence interval (CI) was estimated using a random-effect model. Heterogeneity was assessed with Cochran's Q and Higgins I 2 tests. Two reviewers assessed trial quality and extracted data independently. The analysis and bias for each included study was performed and assessed using Review Manager 5.2. Results: Eighteen randomized, placebo-controlled studies (n = 1056 participants, 527 consuming probiotics, 529 not consuming probiotics) were included for analysis. Comparing the probiotics groups with the control groups, there were statistically significant pooled standardized

show abstract

“…One of the main secreted products from Lf5221 is FA, produced through its intrinsic ferulic acid esterase (FAE) activity. Previously, there have been several indications in human clinical trials that probiotics have a beneficial effect on various markers of metabolic syndrome including B. lactis [26], L. plantarum [27], L. rhamnosus [28], L. gasseri [29] and L. reuteri [25]. There are also conflicting studies showing that probiotics have a less beneficial effect on the aforementioned markers including L. casei Shirota [30].…”

Section: Discussionmentioning

confidence: 99%